Latest Information Update: 09 Mar 1999
At a glance
- Originator Merck & Co
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Osteoarthritis in USA (Unknown route)
- 22 Jan 1996 New profile
- 22 Jan 1996 Preclinical development for Osteoarthritis in USA (Unknown route)